Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGNNASDAQ:NRXSNASDAQ:OSRHOTCMKTS:SIGY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$4.54+33.5%$2.25$1.55▼$5.90$52.01M1.2423,022 shs1.66 million shsNRXSNeurAxis$2.86+2.1%$2.21$1.33▼$6.20$20.64M3.34406,157 shs478,931 shsOSRHOSR$1.22+9.9%$1.50$1.02▼$13.40$23.52M1.542.98 million shs151,844 shsSIGYSigyn Therapeutics$2.49-29.5%$3.82$2.49▼$5.75$4.00M-1.03466 shs795 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies+76.17%+71.72%+51.65%-2.86%-42.86%NRXSNeurAxis-5.41%-12.50%+16.67%+32.70%-11.39%OSRHOSR-1.77%-3.44%-19.86%-66.57%+110,999,900.00%SIGYSigyn Therapeutics-29.46%-29.46%-29.46%-39.41%-52.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies2.3809 of 5 stars3.73.00.00.03.00.00.6NRXSNeurAxisN/AN/AN/AN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AN/AN/AN/ASIGYSigyn TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$11.50153.30% UpsideNRXSNeurAxis 0.00N/AN/AN/AOSRHOSR 0.00N/AN/AN/ASIGYSigyn Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SIGY, NRXS, CLGN, and OSRH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/27/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$515K100.98N/AN/A$2.47 per share1.84NRXSNeurAxis$2.93M7.03N/AN/A($0.27) per share-10.59OSRHOSR-$148.95K-157.89N/AN/AN/A∞SIGYSigyn TherapeuticsN/AN/AN/AN/A($2.80) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$7.02M-$1.46N/AN/AN/A-2,680.00%-77.05%-61.43%6/4/2025 (Estimated)NRXSNeurAxis-$14.63M-$1.19N/A∞N/A-492.76%N/A-641.25%N/AOSRHOSRN/AN/A0.00∞N/AN/AN/AN/AN/ASIGYSigyn Therapeutics-$4.15M-$4.57N/A∞N/AN/AN/A-1,147.41%N/ALatest SIGY, NRXS, CLGN, and OSRH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 million5/20/2025Q1 2025OSRHOSRN/A-$1.04N/A-$1.04N/A$0.76 million5/20/2025Q1 2025SIGYSigyn TherapeuticsN/A-$0.42N/A-$0.42N/AN/A4/15/2025Q4 2024SIGYSigyn TherapeuticsN/A-$2.51N/A-$2.51N/AN/A3/26/2025Q4 2024CLGNCollPlant Biotechnologies-$0.42-$0.34+$0.08-$0.34$0.36 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ANRXSNeurAxisN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ASIGYSigyn TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A5.385.23NRXSNeurAxisN/A0.240.23OSRHOSRN/AN/AN/ASIGYSigyn TherapeuticsN/A0.060.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%NRXSNeurAxis11.77%OSRHOSR55.30%SIGYSigyn Therapeutics10.01%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%NRXSNeurAxis26.40%OSRHOSR33.67%SIGYSigyn Therapeutics78.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7011.46 million10.36 millionOptionableNRXSNeurAxis197.22 million6.09 millionNot OptionableOSRHOSRN/A19.28 million2.68 millionN/ASIGYSigyn Therapeutics51.61 million346,000Not OptionableSIGY, NRXS, CLGN, and OSRH HeadlinesRecent News About These CompaniesSigyn Therapeutics Delays Q1 2025 10-Q FilingMay 15, 2025 | tipranks.comSigyn Therapeutics Delays Yearly Report FilingMarch 31, 2025 | tipranks.comSigyn CEO Note: An Emerging New Industry, 15 Years in the MakingMarch 12, 2025 | finance.yahoo.comSigyn CEO Note: Combating the Rising Threat of New Pandemic VirusesMarch 5, 2025 | finance.yahoo.comSigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare AnalystFebruary 25, 2025 | finance.yahoo.comSigyn Therapeutics to Present at Tomorrow’s Small Cap Growth Virtual Investor ConferenceFebruary 5, 2025 | financialpost.comSigyn Therapeutics to Present at Tomorrow's Small Cap Growth Virtual Investor ConferenceFebruary 5, 2025 | globenewswire.comSigyn Therapeutics Announces the Appointment of Michael Ryan to Its Board of DirectorsJanuary 29, 2025 | finance.yahoo.comSigyn Therapeutics, Inc. (SIGY)December 21, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 76 Day 2 on October 31 Register NowOctober 30, 2024 | markets.businessinsider.comPresenting on the Emerging Growth Conference 74 Day 2 on August 22 Register NowAugust 21, 2024 | finance.yahoo.comOTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand ViewingAugust 2, 2024 | finance.yahoo.comSigyn Therapeutics Reports First Quarter 2024 Financial ResultsMay 15, 2024 | finance.yahoo.comSigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"May 7, 2024 | finance.yahoo.comSigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth ConferenceMarch 5, 2024 | finance.yahoo.comSigyn Therapeutics to Present at Tomorrow's Emerging Growth ConferenceMarch 5, 2024 | finance.yahoo.comSigyn Therapeutics™ to Present at Tomorrow's Emerging Growth ConferenceMarch 5, 2024 | globenewswire.comSigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-KFebruary 21, 2024 | globenewswire.comSigyn Therapeutics, Inc.: Sigyn Therapeutics Completes Reverse Stock SplitFebruary 3, 2024 | finanznachrichten.deSigyn Therapeutics Announces 1-for-40 Reverse Stock SplitFebruary 2, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIGY, NRXS, CLGN, and OSRH Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$4.54 +1.14 (+33.53%) Closing price 04:00 PM EasternExtended Trading$4.44 -0.09 (-2.09%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.NeurAxis NASDAQ:NRXS$2.86 +0.06 (+2.14%) Closing price 04:00 PM EasternExtended Trading$2.85 -0.01 (-0.35%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.OSR NASDAQ:OSRH$1.22 +0.11 (+9.91%) As of 04:00 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Sigyn Therapeutics OTCMKTS:SIGY$2.49 -1.04 (-29.46%) As of 05/28/2025 12:52 PM EasternSigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
